Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor

• David Sanford,
• Hagop Kantarjian,
• Jeffrey Skinner,
• Elias Jabbour,
• Jorge Cortes

Affiliations

David Sanford

The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

Hagop Kantarjian

The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

Jeffrey Skinner

The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

Elias Jabbour

The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

Jorge Cortes

The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA